Results 181 to 190 of about 3,342,563 (345)

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Comparative Transcriptomic Analysis Identifies Predictive Biomarkers of Pathological Complete Response in Triple-negative Breast Cancer. [PDF]

open access: yesCancer Genomics Proteomics
Chen FM   +16 more
europepmc   +1 more source

Methylation Specific PCR (MSP): Nested PCR vs Unnested PCR

open access: yes, 2023
Farizky Martriano Humardani   +7 more
openaire   +1 more source

Key performance evaluation of commercialized multiplex rRT-PCR kits for respiratory viruses: implications for application and optimization

open access: gold
Wenqian Feng   +12 more
openalex   +1 more source

Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR [PDF]

open access: bronze, 2012
Stephanie A. Kazane   +6 more
openalex   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

open access: yesFEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy